Phase 1 dose escalation of ACM-CpG, a polymersome-delivered TLR9 agonist for advanced solid tumors after prior treatment with checkpoint inhibitor.
Sep 3, 2026/Academic Journal
Jain, Amit, Tan, Aaron C., Budiman, Andrea, Tan, Kim Peng, Jackwee, Lim, Ser Yue, Loo, Jian Hang, Lam, Yan Jun, Lee, Chia, Teck Wan, Schultheis, Katherine, Jiang, Nan, Nallani, Madhavan, Tan, Daniel Shao-Weng
JTS CPG Development Process.
Sep 3, 2026/Academic Journal
Spott, Mary Ann, Burelison, Dallas R, Kurkowski, Cynthia R, Stockinger, Zsolt T